tetano
Editor, Senior Moderator
Sci Rep
. 2021 Mar 3;11(1):5087.
doi: 10.1038/s41598-021-84539-5.
Non-steroidal anti-inflammatory agent use may not be associated with mortality of coronavirus disease 19
Jungchan Park[SUP] #[/SUP][SUP] 1 [/SUP], Seung-Hwa Lee[SUP] #[/SUP][SUP] 2 [/SUP], Seng Chan You[SUP] 3 [/SUP], Jinseob Kim[SUP] 4 [/SUP], Kwangmo Yang[SUP] #[/SUP][SUP] 5 [/SUP]
Affiliations
Abstract
Non-steroidal anti-inflammatory drugs (NSAIDs) have been widely used in patients with respiratory infection, but their safety in coronavirus disease 19 (Covid-19) patients has not been fully investigated. We evaluated an association between NSAID use and outcomes of Covid-19. This study was a retrospective observational cohort study based on insurance benefit claims sent to the Health Insurance Review and Assessment Service of Korea by May 15, 2020. These claims comprised all Covid-19-tested cases and history of medical service use for the past 3 years in these patients. The primary outcome was all-cause mortality, and the secondary outcome was need for ventilator care. Among 7590 patients diagnosed with Covid-19, two distinct cohorts were generated based on NSAID or acetaminophen prescription within 2 weeks before Covid-19 diagnosis. A total of 398 patients was prescribed NSAIDs, and 2365 patients were prescribed acetaminophen. After propensity score matching, 397 pairs of data set were generated, and all-cause mortality of the NSAIDs group showed no significant difference compared with the acetaminophen group (4.0% vs. 3.0%; hazard ratio
, 1.33; 95% confidence interval [CI], 0.63-2.88; P = 0.46). The rate of ventilator care also did not show significantly different results between the two groups (2.0% vs. 1.3%; HR, 1.60; 95% CI 0.53-5.30; P = 0.42). Use of NSAIDs was not associated with mortality or ventilator care in Covid-19 patients. NSAIDs may be safely used to relieve symptoms in patients with suspicion of Covid-19.
. 2021 Mar 3;11(1):5087.
doi: 10.1038/s41598-021-84539-5.
Non-steroidal anti-inflammatory agent use may not be associated with mortality of coronavirus disease 19
Jungchan Park[SUP] #[/SUP][SUP] 1 [/SUP], Seung-Hwa Lee[SUP] #[/SUP][SUP] 2 [/SUP], Seng Chan You[SUP] 3 [/SUP], Jinseob Kim[SUP] 4 [/SUP], Kwangmo Yang[SUP] #[/SUP][SUP] 5 [/SUP]
Affiliations
- PMID: 33658615
- DOI: 10.1038/s41598-021-84539-5
Abstract
Non-steroidal anti-inflammatory drugs (NSAIDs) have been widely used in patients with respiratory infection, but their safety in coronavirus disease 19 (Covid-19) patients has not been fully investigated. We evaluated an association between NSAID use and outcomes of Covid-19. This study was a retrospective observational cohort study based on insurance benefit claims sent to the Health Insurance Review and Assessment Service of Korea by May 15, 2020. These claims comprised all Covid-19-tested cases and history of medical service use for the past 3 years in these patients. The primary outcome was all-cause mortality, and the secondary outcome was need for ventilator care. Among 7590 patients diagnosed with Covid-19, two distinct cohorts were generated based on NSAID or acetaminophen prescription within 2 weeks before Covid-19 diagnosis. A total of 398 patients was prescribed NSAIDs, and 2365 patients were prescribed acetaminophen. After propensity score matching, 397 pairs of data set were generated, and all-cause mortality of the NSAIDs group showed no significant difference compared with the acetaminophen group (4.0% vs. 3.0%; hazard ratio
, 1.33; 95% confidence interval [CI], 0.63-2.88; P = 0.46). The rate of ventilator care also did not show significantly different results between the two groups (2.0% vs. 1.3%; HR, 1.60; 95% CI 0.53-5.30; P = 0.42). Use of NSAIDs was not associated with mortality or ventilator care in Covid-19 patients. NSAIDs may be safely used to relieve symptoms in patients with suspicion of Covid-19.